Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A bioassay for HIV-1 based on Env-CD4 interaction.

V Ciminale1, B K Felber, M Campbell

  • 1National Cancer Institute-Frederick Cancer Research and Development Center, ABL-Basic Research Program, Frederick, MD 21702-1201.

AIDS Research and Human Retroviruses
|November 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlates of HIV-1 control after combination immunotherapy.

Nature·2025
Same author

Combination immunotherapy induces post-intervention control of HIV.

Research square·2025
Same author

Recombinant human heterodimeric IL-15 complex displays extensive and reproducible N- and O-linked glycosylation.

Glycoconjugate journal·2015
Same author

Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells.

Gene therapy·2014
Same author

CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection.

Mucosal immunology·2008
Same author

Macaques co-immunized with SIVgag/pol-HIVenv and IL-12 plasmid have increased cellular responses.

Journal of medical primatology·2007

Researchers developed a novel bioassay to screen drugs targeting HIV-1 entry. This assay measures cell fusion, offering a fast and quantitative method to identify inhibitors of the CD4-Env interaction crucial for viral infection.

Area of Science:

  • Virology
  • Immunology
  • Biotechnology

Background:

  • The initial step of human immunodeficiency virus type 1 (HIV-1) infection involves the binding of the viral envelope glycoprotein gp120 (Env) to the CD4 receptor on host cells.
  • This critical interaction presents a significant target for developing antiviral therapies aimed at blocking HIV-1 entry.

Purpose of the Study:

  • To develop a simple, rapid, and quantitative bioassay for screening and evaluating drugs that inhibit the interaction between HIV-1 Env and CD4.
  • To create a tool for assessing potential therapeutic interventions targeting the initial stages of HIV-1 infection.

Main Methods:

  • Development of two stably transfected cell lines: HL2/3 (expressing HIV-1 proteins, including gp120env) and HLCD4-CAT (expressing CD4 receptor and a CAT reporter gene under HIV-1 LTR control).

Related Experiment Videos

  • Co-cultivation of HL2/3 and HLCD4-CAT cells to induce cell-cell fusion mediated by the gp120-CD4 interaction.
  • Quantification of fusion efficiency through visual assessment and measurement of chloramphenicol acetyltransferase (CAT) enzyme activity.

    • Main Results:

    • The co-cultivation of HL2/3 and HLCD4-CAT cells resulted in efficient cell fusion within 8 hours.
    • The developed bioassay provides a quantitative measure of fusion efficiency via CAT enzyme activity.
    • The HL2/3 cell line is capable of secreting gp120env, enabling its use for Env protein production.

    Conclusions:

    • A novel, quantitative bioassay has been successfully established to measure HIV-1 Env-CD4-mediated cell fusion.
    • This assay serves as an effective tool for screening and identifying potential drug candidates that interfere with HIV-1 entry.
    • The system facilitates the development of new therapeutic strategies against HIV-1 infection by targeting the Env-CD4 binding event.